The street.com now tracks all his stocks performances that he talks about on Mad Money
http://madmoney.thestreet.com/
http://madmoney.thestreet.com/
I didnt know the show was taped thought it was live be nice to be a fly on the wall cramer does move stocks in after hour trading.
<TABLE width=175 align=left><TBODY><TR><TD width=168></TD><TD>
</TD></TR></TBODY></TABLE>
Financial Services
Funny Money
Peter Lattman,
Aug. 2 was a lackluster day in the trading of high-flying tech stock Syneron Medical. It barely budged, dropping a mere 9 cents to $40.85. After-hours action also looked blasé until 5:33 P.M. EST, when "freedompartner" posted this on Yahoo!: "Cramer said buy ELOS before earnings: Just finished taping the show. He loves ELOS." The message referred to market pundit James Cramer and his wildly successful CNBC show, Mad Money.
Syneron (nasdaq: ELOS - news - people ) began moving higher and trading picked up. That night on Mad Money, which CNBC tapes from 4:30 P.M. to 5:30 P.M. EST and broadcasts from 6:00 P.M. to 7:00 P.M. EST, Cramer indeed touted Syneron's laser products' ability to smooth away cellulite. "I am sticking the proverbial neck out" and telling you to buy ELOS now before earnings, he exclaimed. The stock spiked to $45.46 in after-hours trading on volume of 300,000 shares.
What happened? Apparently someone called Mad Money during taping for the Q&A segment, heard the tout while on hold and disseminated the information on the Web before the show aired, against CNBC's admonition.
A taped recording warns callers that they will hear the show and must agree to not disclose or trade on information discussed prior to that information being mentioned during the during the 6 P.M. airing. "This is extremely important," counsels the recording, "and if you cannot abide by this rule, please hang up now."
Transgressors can, of course, ignore the instructions, remain on the line and spread Cramer's picks. Should that happen, says a CNBC spokesperson, that person "would be banned from participating in all future programs, and the network will consider appropriate legal action based on the specific facts involved."
As it happens, viewers who bought ELOS got burned two days later. Syneron's earnings disappointed, and the stock fell back to its earlier level. On Thursday, it was trading at $36.83.
For two decades, Cramer, 50, has told America what to buy and sell in print (SmartMoney, Time, New York), on the Web (TheStreet.com), on a radio show and now on TV. He also ran a hedge fund, Cramer Berkowitz, that claimed a 24% annual return, after fees, over 15 years. He burned out and retired in 2001.
Since its March debut, Mad Money has become CNBC's second-highest-rated program, in what was previously its lowest-rated time slot (except for the 5 A.M. show), drawing nearly 200,000 viewers five nights per week. The show amounts to Cramer being Cramer--as raw and uncensored as ever. He feverishly bounces around the studio, rants at the camera and bangs on buttons blaring the sound effects of cash registers and bowling pins, growling bears and raging bulls.
He's also spawned a burgeoning subculture of trading types looking to make a quick buck off of his calls. With a flat market and dormant volatility, brokers and traders are desperate for anything that moves stocks, and in Mad Money they've found their Messiah.
Aside from Yahoo!'s (nasdaq: YHOO - news - people ) boards, which are replete with Cramer references, there are at least three independent Web sites devoted to Mad Money. (Cramer's TheStreet.com also devotes substantial coverage to the show.) It's not just chat-roomers paying attention. Brokerages such as Cantor Fitzgerald include Cramer's picks in their research notes, which are distributed to mutual fund and hedge fund clients.
"At first, we didn't cover Mad Money's picks, but our customers kept talking about the show's impact," says Damon Southward of Briefing.com, a news service used by investors that now includes the show's content in its product. "We need to stay on top of volatility, and if there's one thing Cramer creates, it's volatility."
Southward says that while he's seen other commentators affect markets, such as Dan Dorfman, Business Week's Gene Marcial and TV host Louis Rukeyeser--Cramer's show has a more widespread impact.
"Cramer weighs in on dozens of stocks every show," explains Southward. "Increasing the show's effect is a robust after-hours trading market--viewers buy and sell stocks while watching the show."
Earlier in his career, Cramer raised eyebrows as one of the first money managers to write about stocks. In 1995, the SEC investigated whether he broke any laws writing columns about his holdings. Cramer was exonerated, but disclosures and disclaimers were added to his stories. They have followed Cramer ever since, but none as long-winded as Mad Money's. In the show's opening minute, a 263-word disclaimer scrolls down the screen (in a tiny font). Callers are subjected to an even lengthier two-minute disclosure recording.
Despite the cautious measures, it appears CNBC is still grappling with the mysterious ways in which Mad Money moves stocks. On Aug. 8 around noon, CNBC announced on its Web site that Charles Goodson, chief executive of PetroQuest Energy (nasdaq: PQUE - news - people ), was going to be Cramer's guest that evening. PetroQuest promptly surged 7% on four times its average volume. Chief executive appearances are typically positive, and Cramer is bullish on oil stocks.
As it turned out, Mad Money had booked Goodson for the following Monday. Informed by Forbes of the error, the network removed Goodson's name from the Web site and canceled his appearance. It also decided to discontinue posting Mad Money guests on its Web site prior to the show's broadcast.
"CNBC will continue to take steps to ensure that the integrity of the program remains intact," says a CNBC spokesperson.
While it might be able to protect the show's integrity, CNBC can't control whether the show achieves its stated goal--making people money.
Last Monday after a weeklong Hawaiian vacation, a bronzed Cramer returned to CNBC's studios as unhinged as ever. He immediately trumpeted his pick of the week--Dick's Sporting Goods (nyse: DKS - news - people ), the athletic-gear and apparel chain.
"This is the best story you've never heard of," he enthused, urging viewers to buy Dick's ahead of its earnings announcement the next morning.
Although Cramer warned his disciples only to buy with a limit order to prevent the stock's spiking, Dick's popped 7% to $41.93, trading 300,000 shares during Mad Money. By comparison, Cisco Systems (nasdaq: CSCO - news - people ), which traded 60 million shares in Monday's regular session, traded only 12,000 shares between 6 P.M. and 7 P.M.
Tuesday morning, Dick's sliced its 2005 earnings forecast, and the stock tanked, closing down 20% at $32.90.
Enraged, Mad Money viewers flooded Dick's Yahoo! message board with anti-Cramer tirades, many of them--there were over 1,800 posts that day--unsuitable for reprinting on a family Web site.
That evening, Cramer--with an "Eating Crow" graphic prominently displayed behind him--issued a mea culpa, repeating five times "I was wrong." But don't dwell on your mistakes, he exhorted: "Bottom line: You have to move on and get back into the game!"
Many Wall Street watchers don't think it's a game.
"Cramer's moving the markets like the star Internet analysts did during the tech bubble," says Jacob Zamansky, an attorney representing individual investors. "He's got a big following of people who think they're acting responsibly by following Cramer's advice--but in reality he's dangerous to their health."
<TABLE width=175 align=left><TBODY><TR><TD width=168></TD><TD>
Financial Services
Funny Money
Peter Lattman,
Aug. 2 was a lackluster day in the trading of high-flying tech stock Syneron Medical. It barely budged, dropping a mere 9 cents to $40.85. After-hours action also looked blasé until 5:33 P.M. EST, when "freedompartner" posted this on Yahoo!: "Cramer said buy ELOS before earnings: Just finished taping the show. He loves ELOS." The message referred to market pundit James Cramer and his wildly successful CNBC show, Mad Money.
Syneron (nasdaq: ELOS - news - people ) began moving higher and trading picked up. That night on Mad Money, which CNBC tapes from 4:30 P.M. to 5:30 P.M. EST and broadcasts from 6:00 P.M. to 7:00 P.M. EST, Cramer indeed touted Syneron's laser products' ability to smooth away cellulite. "I am sticking the proverbial neck out" and telling you to buy ELOS now before earnings, he exclaimed. The stock spiked to $45.46 in after-hours trading on volume of 300,000 shares.
What happened? Apparently someone called Mad Money during taping for the Q&A segment, heard the tout while on hold and disseminated the information on the Web before the show aired, against CNBC's admonition.
A taped recording warns callers that they will hear the show and must agree to not disclose or trade on information discussed prior to that information being mentioned during the during the 6 P.M. airing. "This is extremely important," counsels the recording, "and if you cannot abide by this rule, please hang up now."
Transgressors can, of course, ignore the instructions, remain on the line and spread Cramer's picks. Should that happen, says a CNBC spokesperson, that person "would be banned from participating in all future programs, and the network will consider appropriate legal action based on the specific facts involved."
As it happens, viewers who bought ELOS got burned two days later. Syneron's earnings disappointed, and the stock fell back to its earlier level. On Thursday, it was trading at $36.83.
For two decades, Cramer, 50, has told America what to buy and sell in print (SmartMoney, Time, New York), on the Web (TheStreet.com), on a radio show and now on TV. He also ran a hedge fund, Cramer Berkowitz, that claimed a 24% annual return, after fees, over 15 years. He burned out and retired in 2001.
Since its March debut, Mad Money has become CNBC's second-highest-rated program, in what was previously its lowest-rated time slot (except for the 5 A.M. show), drawing nearly 200,000 viewers five nights per week. The show amounts to Cramer being Cramer--as raw and uncensored as ever. He feverishly bounces around the studio, rants at the camera and bangs on buttons blaring the sound effects of cash registers and bowling pins, growling bears and raging bulls.
He's also spawned a burgeoning subculture of trading types looking to make a quick buck off of his calls. With a flat market and dormant volatility, brokers and traders are desperate for anything that moves stocks, and in Mad Money they've found their Messiah.
Aside from Yahoo!'s (nasdaq: YHOO - news - people ) boards, which are replete with Cramer references, there are at least three independent Web sites devoted to Mad Money. (Cramer's TheStreet.com also devotes substantial coverage to the show.) It's not just chat-roomers paying attention. Brokerages such as Cantor Fitzgerald include Cramer's picks in their research notes, which are distributed to mutual fund and hedge fund clients.
"At first, we didn't cover Mad Money's picks, but our customers kept talking about the show's impact," says Damon Southward of Briefing.com, a news service used by investors that now includes the show's content in its product. "We need to stay on top of volatility, and if there's one thing Cramer creates, it's volatility."
Southward says that while he's seen other commentators affect markets, such as Dan Dorfman, Business Week's Gene Marcial and TV host Louis Rukeyeser--Cramer's show has a more widespread impact.
"Cramer weighs in on dozens of stocks every show," explains Southward. "Increasing the show's effect is a robust after-hours trading market--viewers buy and sell stocks while watching the show."
Earlier in his career, Cramer raised eyebrows as one of the first money managers to write about stocks. In 1995, the SEC investigated whether he broke any laws writing columns about his holdings. Cramer was exonerated, but disclosures and disclaimers were added to his stories. They have followed Cramer ever since, but none as long-winded as Mad Money's. In the show's opening minute, a 263-word disclaimer scrolls down the screen (in a tiny font). Callers are subjected to an even lengthier two-minute disclosure recording.
Despite the cautious measures, it appears CNBC is still grappling with the mysterious ways in which Mad Money moves stocks. On Aug. 8 around noon, CNBC announced on its Web site that Charles Goodson, chief executive of PetroQuest Energy (nasdaq: PQUE - news - people ), was going to be Cramer's guest that evening. PetroQuest promptly surged 7% on four times its average volume. Chief executive appearances are typically positive, and Cramer is bullish on oil stocks.
As it turned out, Mad Money had booked Goodson for the following Monday. Informed by Forbes of the error, the network removed Goodson's name from the Web site and canceled his appearance. It also decided to discontinue posting Mad Money guests on its Web site prior to the show's broadcast.
"CNBC will continue to take steps to ensure that the integrity of the program remains intact," says a CNBC spokesperson.
While it might be able to protect the show's integrity, CNBC can't control whether the show achieves its stated goal--making people money.
Last Monday after a weeklong Hawaiian vacation, a bronzed Cramer returned to CNBC's studios as unhinged as ever. He immediately trumpeted his pick of the week--Dick's Sporting Goods (nyse: DKS - news - people ), the athletic-gear and apparel chain.
"This is the best story you've never heard of," he enthused, urging viewers to buy Dick's ahead of its earnings announcement the next morning.
Although Cramer warned his disciples only to buy with a limit order to prevent the stock's spiking, Dick's popped 7% to $41.93, trading 300,000 shares during Mad Money. By comparison, Cisco Systems (nasdaq: CSCO - news - people ), which traded 60 million shares in Monday's regular session, traded only 12,000 shares between 6 P.M. and 7 P.M.
Tuesday morning, Dick's sliced its 2005 earnings forecast, and the stock tanked, closing down 20% at $32.90.
Enraged, Mad Money viewers flooded Dick's Yahoo! message board with anti-Cramer tirades, many of them--there were over 1,800 posts that day--unsuitable for reprinting on a family Web site.
That evening, Cramer--with an "Eating Crow" graphic prominently displayed behind him--issued a mea culpa, repeating five times "I was wrong." But don't dwell on your mistakes, he exhorted: "Bottom line: You have to move on and get back into the game!"
Many Wall Street watchers don't think it's a game.
"Cramer's moving the markets like the star Internet analysts did during the tech bubble," says Jacob Zamansky, an attorney representing individual investors. "He's got a big following of people who think they're acting responsibly by following Cramer's advice--but in reality he's dangerous to their health."
I am in the "business" and I have a degree of respect for Cramer as he has excellent contacts and good insights as to how the market works.
My problem with this guy is that he is way too momemtum driven. I cannot fathom how an individual investor can buy/trade in the matter in which he prescribes stocks. Additonally his opinion on sectors/stocks shifts like the wind, one minute he hates pharma next he loves it, one day he touts the housing sector the next week it is a sell. Says to buy only best of breed companies then touts 3rd tier software plays, lots of inconsistencies...
Above all else this guy is best at promoting himself and after a while his show can be a grind to watch.
My problem with this guy is that he is way too momemtum driven. I cannot fathom how an individual investor can buy/trade in the matter in which he prescribes stocks. Additonally his opinion on sectors/stocks shifts like the wind, one minute he hates pharma next he loves it, one day he touts the housing sector the next week it is a sell. Says to buy only best of breed companies then touts 3rd tier software plays, lots of inconsistencies...
Above all else this guy is best at promoting himself and after a while his show can be a grind to watch.
He does move the market said the stock NMTI could get to $100 it moved from 17 to 22 right after he mention it.
Cramer's 'Mad Money' Recap: Headache Relief for Investors
By TheStreet.com Staff
1/27/2006 7:30 PM EST
"I have a $17 stock for you that, if everything goes right, could easily trade up to $100 per share," Jim Cramer told viewers of his "Mad Money" TV show Friday.
The stock is NMT Medical (NMTI:Nasdaq - news - research - Cramer's Take).
It's not a buy-and-hold play, he said, but if you're willing to take some risk it could possibly make you some money fast off of people who suffer from severe migraines.
There's a heart defect called patent foramen ovale (PFO) that affects one in five people and has been connected with an increased likelihood that a person will have migraines, Cramer said. If you close the hole in the heart caused by the defect, it could have a profound impact.
NMT Medical has an implantable, stent-like device called CardioSEAL that could help plug this hole and is already being used to help with strokes, he said. And right now the company is trial testing the device to prove its effectiveness.
If the trial works, I think you'll be hearing about it and paying $100 a share, Cramer said. But, he cautioned, the stock could go below $10 if the trial testing don't work out for the company.
Still, Cramer thinks the potential upside outweighs the downside.
He admitted that he can't say with any authority which way the study will go, but he can say what it will mean if the study shows that the product works.
He came up with the $100-a-share number by looking at the figures NMT Medical offers, including the fact that 3 million people get migraines with aura, the kind associated with the PFO heart defect. These are people who miss work because their migraines are so bad, he added.
Cramer's 'Mad Money' Recap: Headache Relief for Investors
By TheStreet.com Staff
1/27/2006 7:30 PM EST
"I have a $17 stock for you that, if everything goes right, could easily trade up to $100 per share," Jim Cramer told viewers of his "Mad Money" TV show Friday.
The stock is NMT Medical (NMTI:Nasdaq - news - research - Cramer's Take).
It's not a buy-and-hold play, he said, but if you're willing to take some risk it could possibly make you some money fast off of people who suffer from severe migraines.
There's a heart defect called patent foramen ovale (PFO) that affects one in five people and has been connected with an increased likelihood that a person will have migraines, Cramer said. If you close the hole in the heart caused by the defect, it could have a profound impact.
NMT Medical has an implantable, stent-like device called CardioSEAL that could help plug this hole and is already being used to help with strokes, he said. And right now the company is trial testing the device to prove its effectiveness.
If the trial works, I think you'll be hearing about it and paying $100 a share, Cramer said. But, he cautioned, the stock could go below $10 if the trial testing don't work out for the company.
Still, Cramer thinks the potential upside outweighs the downside.
He admitted that he can't say with any authority which way the study will go, but he can say what it will mean if the study shows that the product works.
He came up with the $100-a-share number by looking at the figures NMT Medical offers, including the fact that 3 million people get migraines with aura, the kind associated with the PFO heart defect. These are people who miss work because their migraines are so bad, he added.
No doubt that he is moving markets. Particularily in smaller stocks which have lower floats...
Trading on his advice in after hours is folly though as you can get your ass handed to you by people looking to offload shares. Best to trade in normal market hours so you truly get a fair bid and ask.
Trading on his advice in after hours is folly though as you can get your ass handed to you by people looking to offload shares. Best to trade in normal market hours so you truly get a fair bid and ask.
Cramer is an ass
the guy is a scam artist.. the biggest hypocrite there is...... 2 days ago he was pumping Google buy before earnings etc etc.. today after the bell it is down 50 yes 50.......... nobody talks about those..... the list goes on and on with this guy.......follow this guy and you will be broke in a heart beat.
the guy is a scam artist.. the biggest hypocrite there is...... 2 days ago he was pumping Google buy before earnings etc etc.. today after the bell it is down 50 yes 50.......... nobody talks about those..... the list goes on and on with this guy.......follow this guy and you will be broke in a heart beat.
another perfect cramer pump
<TABLE id=yfncsumtab cellSpacing=0 cellPadding=0 width=580 border=0><TBODY><TR vAlign=top><TD width="100%" colSpan=3><TABLE class=yfnc_modtitlew1 cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR class=yfnc_modtitle1><TD><SMALL>OCCULOGIX, INC. (NasdaqNM:RHEO) Delayed quote data</SMALL></TD><TD align=right>
</TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=0 width=1 border=0><TBODY><TR><TD height=1><SPACER width="1" type="block" height="1"></TD></TR></TBODY></TABLE><TABLE class=yfnc_modtitlew1 cellSpacing=0 cellPadding=0 width=580 border=0><TBODY><TR><TD colSpan=5><TABLE cellPadding=1 width="100%"><TBODY><TR><TD></TD></TR></TBODY></TABLE></TD></TR><TR vAlign=top><TD><TABLE class=yfncsumdatagrid cellSpacing=0 cellPadding=0 width=185 border=0><TBODY><TR vAlign=top><TD class=yfnc_datamodoutline1><TABLE cellSpacing=1 cellPadding=2 width="100%" border=0><TBODY><TR><TD class=yfnc_tablehead1 width="48%">Last Trade:</TD><TD class=yfnc_tabledata1><BIG>4.10</BIG></TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Trade Time:</TD><TD class=yfnc_tabledata1>Feb 3</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Change:</TD><TD class=yfnc_tabledata1>
8.65 (67.84%) </TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Prev Close:</TD><TD class=yfnc_tabledata1>12.75</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Open:</TD><TD class=yfnc_tabledata1>3.75</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Bid:</TD><TD class=yfnc_tabledata1>4.10<SMALL> x 200</SMALL> </TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Ask:</TD><TD class=yfnc_tabledata1>4.15<SMALL> x 1500</SMALL> </TD></TR><TR><TD class=yfnc_tablehead1 width="48%">1y Target Est:</TD><TD class=yfnc_tabledata1>13.00</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></TD><TD noWrap width=5><SPACER width="5" type="block" height="1"></SPACER></TD><TD><TABLE class=yfncsumdatagrid cellSpacing=0 cellPadding=0 width=185 border=0><TBODY><TR vAlign=top><TD class=yfnc_datamodoutline1><TABLE cellSpacing=1 cellPadding=2 width="100%" border=0><TBODY><TR><TD class=yfnc_tablehead1 width="48%">Day's Range:</TD><TD class=yfnc_tabledata1>3.65 - 5.06</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">52wk Range:</TD><TD class=yfnc_tabledata1>3.65 - 12.85</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Volume:</TD><TD class=yfnc_tabledata1>21,753,504</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Avg Vol <SMALL>(3m)</SMALL>:</TD><TD class=yfnc_tabledata1>789,712</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Market Cap:</TD><TD class=yfnc_tabledata1>172.45M</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">P/E <SMALL>(ttm)</SMALL>:</TD><TD class=yfnc_tabledata1>N/A</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">EPS <SMALL>(ttm)</SMALL>:</TD><TD class=yfnc_tabledata1>-0.67</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Div & Yield:</TD><TD class=yfnc_tabledata1>N/A (N/A)</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></TD><TD noWrap width=5><SPACER width="5" type="block" height="1"></SPACER></TD><TD vAlign=center align=middle width=193>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD height=1><SPACER width="1" type="block" height="1"></TD></TR></TBODY></TABLE><SMALL>1d 5d 3m 6m 1y 2y http://finance.yahoo.com/q/bc?s=RHEO&t=</SMALL><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD height=10><SPACER width="1" type="block" height="1"></SPACER></TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=6 width="99%" border=0><TBODY><TR><TD vAlign=center align=middle><SMALL>Annual Report for RHEO</SMALL></TD></TR></TBODY></TABLE>
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>Cramer was pumping this baby 2 weeks ago and look what happened when there technology was proved worthless...
The Eyes Have It
<TABLE cellSpacing=0 cellPadding=5 width=336 align=right border=0><TBODY><TR><TD align=middle><TABLE cellSpacing=0 cellPadding=5 align=right border=0><TBODY><TR><TD width=336 height=280><NOLAYER></NOLAYER><ILAYER id=bigunit width="336" height="280" visibility="hidden"></ILAYER></TD></TR></TBODY></TABLE><!--#config timefmt="%I%M%S" --><!--Fri Feb 03 07:45:24 EST 2006-->
<TABLE cellSpacing=0 cellPadding=0 width=336 align=center bgColor=#ffffff border=0><TBODY><TR><TD>
</TD></TR><TR><TD style="BORDER-RIGHT: #d9dadb 1px solid; BORDER-TOP: #d9dadb 0px solid; BORDER-LEFT: #d9dadb 1px solid; BORDER-BOTTOM: #d9dadb 1px solid">
</TD></TR></TBODY></TABLE>
</TD></TR></TBODY></TABLE>It's time to buy the greatest medical stock you've never heard, Jim Cramer told his "Mad Money" TV show viewers Thursday, and that stock is OccuLogix (RHEO:Nasdaq - commentary - research - Cramer's Take).
People aren't just paying for vanity as they age, they'd also like to be able to see, Cramer said. But those who suffer from age-related macular degeneration are losing their eyesight.
There are treatments on the market for wet macular degeneration, but there's really nothing out there for dry macular degeneration, which usually comes first. But OccuLogix has a blood filtration procedure to treat dry macular degeneration, and Cramer said that this could mean mad money.
<TABLE id=yfncsumtab cellSpacing=0 cellPadding=0 width=580 border=0><TBODY><TR vAlign=top><TD width="100%" colSpan=3><TABLE class=yfnc_modtitlew1 cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR class=yfnc_modtitle1><TD><SMALL>OCCULOGIX, INC. (NasdaqNM:RHEO) Delayed quote data</SMALL></TD><TD align=right>
</TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=0 width=1 border=0><TBODY><TR><TD height=1><SPACER width="1" type="block" height="1"></TD></TR></TBODY></TABLE><TABLE class=yfnc_modtitlew1 cellSpacing=0 cellPadding=0 width=580 border=0><TBODY><TR><TD colSpan=5><TABLE cellPadding=1 width="100%"><TBODY><TR><TD></TD></TR></TBODY></TABLE></TD></TR><TR vAlign=top><TD><TABLE class=yfncsumdatagrid cellSpacing=0 cellPadding=0 width=185 border=0><TBODY><TR vAlign=top><TD class=yfnc_datamodoutline1><TABLE cellSpacing=1 cellPadding=2 width="100%" border=0><TBODY><TR><TD class=yfnc_tablehead1 width="48%">Last Trade:</TD><TD class=yfnc_tabledata1><BIG>4.10</BIG></TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Trade Time:</TD><TD class=yfnc_tabledata1>Feb 3</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Change:</TD><TD class=yfnc_tabledata1>
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>Cramer was pumping this baby 2 weeks ago and look what happened when there technology was proved worthless...
The Eyes Have It
<TABLE cellSpacing=0 cellPadding=5 width=336 align=right border=0><TBODY><TR><TD align=middle><TABLE cellSpacing=0 cellPadding=5 align=right border=0><TBODY><TR><TD width=336 height=280><NOLAYER></NOLAYER><ILAYER id=bigunit width="336" height="280" visibility="hidden"></ILAYER></TD></TR></TBODY></TABLE><!--#config timefmt="%I%M%S" --><!--Fri Feb 03 07:45:24 EST 2006-->
<TABLE cellSpacing=0 cellPadding=0 width=336 align=center bgColor=#ffffff border=0><TBODY><TR><TD>
1. Google Misses by a Mile
2. Google Chief Sells at the Right Time
3. These Energy Stocks Have the Joules
4. Wipeout at Amazon.com
5. Gurus Think Tech Has Turned a Corner
2. Google Chief Sells at the Right Time
3. These Energy Stocks Have the Joules
4. Wipeout at Amazon.com
5. Gurus Think Tech Has Turned a Corner
</TD></TR></TBODY></TABLE>It's time to buy the greatest medical stock you've never heard, Jim Cramer told his "Mad Money" TV show viewers Thursday, and that stock is OccuLogix (RHEO:Nasdaq - commentary - research - Cramer's Take).
People aren't just paying for vanity as they age, they'd also like to be able to see, Cramer said. But those who suffer from age-related macular degeneration are losing their eyesight.
There are treatments on the market for wet macular degeneration, but there's really nothing out there for dry macular degeneration, which usually comes first. But OccuLogix has a blood filtration procedure to treat dry macular degeneration, and Cramer said that this could mean mad money.
